[1] |
Bean SF, Good RA, Windhorst DB. Bullous pemphigoid in an 11⁃year⁃old boy[J]. Arch Dermatol, 1970,102(2):205⁃208.
|
[2] |
Bastuji⁃Garin S, Joly P, Picard⁃Dahan C, et al. Drugs associated with bullous pemphigoid. A case⁃control study[J]. Arch Dermatol, 1996,132(3):272⁃276.
|
[3] |
王媛, 冯素英. 药物诱发大疱性类天疱疮的研究进展[J]. 中华皮肤科杂志, 2020,53(6):487⁃489. doi: 10.35541/cjd.2019 0185.
|
[4] |
Stavropoulos PG, Soura E, Antoniou C. Drug⁃induced pemphigoid: a review of the literature[J]. J Eur Acad Dermatol Venereol, 2014,28(9):1133⁃1140. doi: 10.1111/jdv.12366.
|
[5] |
Nishie W. Dipeptidyl peptidase IV inhibitor⁃associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics[J]. Immunol Med, 2019,42(1):22⁃28. doi: 10. 1080/25785826.2019.1619233.
|
[6] |
Lee SG, Lee HJ, Yoon MS, et al. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes[J]. JAMA Dermatol, 2019,155(2):172⁃177. doi: 10.1001/jamadermatol.2018.4556.
|
[7] |
王娣, 陈喜雪, 朱学骏. 124例大疱性类天疱疮治疗回顾[J]. 中华皮肤科杂志, 2007,40(1):7⁃9. doi: 10.3760/j.issn:0412⁃4030.2007.01.005.
|
[8] |
李浩, 林景荣, 刘晓明, 等. 并发神经系统疾病的大疱性类天疱疮临床特点和预后的比较研究[J]. 临床皮肤科杂志, 2015,44(3):152⁃154.
|
[9] |
Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase⁃4 inhibitor⁃associated bullous pemphigoid[J]. Front Immunol, 2019,10:1238. doi: 10.3389/fimmu.2019.01238.
|
[10] |
Reolid A, Muñoz⁃Aceituno E, Rodríguez⁃Jiménez P, et al. Bullous pemphigoid associated with dipeptidyl peptidase⁃4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database[J]. Int J Dermatol, 2020,59(2):197⁃206. doi: 10.1111/ijd.14658.
|
[11] |
Kridin K, Bergman R. Association of bullous pemphigoid with dipeptidyl⁃peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients[J]. JAMA Dermatol, 2018,154(10):1152⁃1158. doi: 10.1001/jamadermatol.2018.2352.
|
[12] |
Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid[J]. J Invest Dermatol, 2016,136(11):2201⁃2210. doi: 10.1016/j.jid.2016.06.622.
|
[13] |
Mai Y, Nishie W, Izumi K, et al. Preferential reactivity of dipeptidyl peptidase⁃IV inhibitor⁃associated bullous pemphigoid autoantibodies to the processed extracellular domains of BP180[J]. Front Immunol, 2019,10:1224. doi: 10.3389/fimmu.2019. 01224.
|
[14] |
Takama H, Yoshida M, Izumi K, et al. Dipeptidyl peptidase⁃4 inhibitor⁃associated bullous pemphigoid: recurrence with epitope spreading[J]. Acta Derm Venereol, 2018,98(10):983⁃984. doi: 10.2340/00015555⁃3010.
|
[15] |
Ständer S, Schmidt E, Zillikens D, et al. More severe erosive phenotype despite lower circulating autoantibody levels in dipeptidyl peptidase⁃4 inhibitor (DPP4i)⁃associated bullous pemphigoid: a retrospective cohort study[J]. Am J Clin Dermatol, 2021,22(1):117⁃127. doi: 10.1007/s40257⁃020⁃00563⁃7.
|
[16] |
Bukvić Mokos Z, Petković M, Balić A, et al. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase⁃4 inhibitors in the elderly: a retrospective study[J]. Croat Med J, 2020,61(2):93⁃99. doi: 10.3325/cmj.2020.61.93.
|
[17] |
Benzaquen M, Borradori L, Berbis P, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case⁃control study from France and Switzerland[J]. J Am Acad Dermatol, 2018,78(6):1090⁃1096. doi: 10.1016/j.jaad.2017.12.038.
|
[18] |
Kridin K. Dipeptidyl⁃peptidase IV inhibitors (DPP4i)⁃associated bullous pemphigoid: estimating the clinical profile and exploring intraclass differences[J]. Dermatol Ther, 2020,33(4):e13790. doi: 10.1111/dth.13790.
|
[19] |
Nieto⁃Benito LM, Bergón⁃Sendín M, Pulido⁃Pérez A, et al. Defining dipeptidyl peptidase⁃4 inhibitors⁃related bullous pemphigoid: a single⁃centre retrospective study[J]. Exp Dermatol, 2021,30(9):1345⁃1351. doi: 10.1111/exd.14387.
|